Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Details
State: Public
Version: Final published version
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_A93C669EA17D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Journal
Cellular and Molecular Life Sciences
ISSN
1420-9071 (Electronic)
ISSN-L
1420-682X
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
69
Number
20
Pages
3395-3418
Language
english
Abstract
Although contributing to inflammatory responses and to the development of certain autoimmune pathologies, type I interferons (IFNs) are used for the treatment of viral, malignant, and even inflammatory diseases. Interleukin-1 (IL-1) is a strongly pyrogenic cytokine and its importance in the development of several inflammatory diseases is clearly established. While the therapeutic use of IL-1 blocking agents is particularly successful in the treatment of innate-driven inflammatory disorders, IFN treatment has mostly been appreciated in the management of multiple sclerosis. Interestingly, type I IFNs exert multifaceted immunomodulatory effects, including the reduction of IL-1 production, an outcome that could contribute to its efficacy in the treatment of inflammatory diseases. In this review, we summarize the current knowledge on IL-1 and IFN effects in different inflammatory disorders, the influence of IFNs on IL-1 production, and discuss possible therapeutic avenues based on these observations.
Keywords
Animals, Humans, Inflammation/drug therapy, Inflammation/metabolism, Interferon Type I/therapeutic use, Interleukin-1/metabolism
Pubmed
Web of science
Open Access
Yes
Create date
18/10/2012 18:06
Last modification date
14/02/2022 8:56